New Research: MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease: Up to 50% of patients with Crohn's disease (CD) experience secondary loss of response (SLR) to infliximab. Patients with SLR… https://t.co/E
RT @IronBiologyBot: Paper alert: MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease http…
Paper alert: MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease https://t.co/Fsv5T33CMs #IronBiology #BioIron #Iron